Zolpimist is a drug owned by Aytu Bioscience Inc. It is protected by 2 US drug patents filed from 2013 to 2016. Out of these, 1 drug patents are active and 1 has expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 07, 2032. Details of Zolpimist's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US8236285 | Buccal, polar and non-polar spray containing zolpidem |
Aug, 2032
(7 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7632517 | Buccal, polar and non-polar spray containing zolpidem |
Oct, 2017
(7 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Zolpimist's patents.
Latest Legal Activities on Zolpimist's Patents
Given below is the list of recent legal activities going on the following patents of Zolpimist.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 15 Jan, 2018 | US7632517 |
| Expire Patent Critical | 02 Sep, 2016 | US8236285 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 09 Apr, 2014 | US7632517 |
| Mail-Petition Decision - Accept Late Payment of Maintenance Fees - Granted Critical | 09 Apr, 2014 | US7632517 |
| Petition Decision - Accept Late Payment of Maintenance Fees - Granted Critical | 09 Apr, 2014 | US7632517 |
| Petition to Accept Late Payment of Maintenance Fee Payment Filed Critical | 09 Apr, 2014 | US7632517 |
| Expire Patent Critical | 10 Jan, 2014 | US7632517 |
| Patent Issue Date Used in PTA Calculation Critical | 07 Aug, 2012 | US8236285 |
| Recordation of Patent Grant Mailed Critical | 07 Aug, 2012 | US8236285 |
| Issue Notification Mailed Critical | 18 Jul, 2012 | US8236285 |
US patents provide insights into the exclusivity only within the United States, but Zolpimist is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zolpimist's family patents as well as insights into ongoing legal events on those patents.
Zolpimist's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zolpimist's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 07, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zolpimist Generic API suppliers:
Zolpidem Tartrate is the generic name for the brand Zolpimist. 30 different companies have already filed for the generic of Zolpimist, with Endo Operations having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Zolpimist's generic
Alternative Brands for Zolpimist
Zolpimist which is used for treating symptoms of transient insomnia., has several other brand drugs using the same active ingredient (Zolpidem Tartrate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Mylan Speciality Lp |
| |
| Purdue Pharma |
| |
| Sanofi Aventis Us |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Zolpidem Tartrate, Zolpimist's active ingredient. Check the complete list of approved generic manufacturers for Zolpimist
About Zolpimist
Zolpimist is a drug owned by Aytu Bioscience Inc. It is used for treating symptoms of transient insomnia. Zolpimist uses Zolpidem Tartrate as an active ingredient. Zolpimist was launched by Aytu in 2008.
Approval Date:
Zolpimist was approved by FDA for market use on 19 December, 2008.
Active Ingredient:
Zolpimist uses Zolpidem Tartrate as the active ingredient. Check out other Drugs and Companies using Zolpidem Tartrate ingredient
Treatment:
Zolpimist is used for treating symptoms of transient insomnia.
Dosage:
Zolpimist is available in spray, metered form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 5MG/SPRAY | SPRAY, METERED | Discontinued | ORAL |